Abstract
Background: Dobutamine pharmodynamics require approximately 10 min to reach steady state. Despite this, standard dobutamine stress echo typically uses 3‐min stages of advancing dobutamine doses because of safety concerns.
Hypothesis: In patients with a high pretest probability of coronary artery disease (CAD), a continuous infusion of high‐dose dobutamine is a feasible and safe method for performing a dobutamine stress test.
Methods: Forty‐seven consecutive patients (mean age 64 ± 11 years) with 3.0 ± 1.4 cardiac risk factors underwent dobutamine stress testing utilizing a single, high‐dose (40 mcg/kg/min), continuous dobutamine infusion. The 40 mcg/kg/min infusion was continued for up to 10 min or until a test end‐point had been reached. If a test endpoint was not achieved, atropine (up to 1.0 mg) was added.
Results: Heart rate rose from 71 ± 12 to 137 ± 18 beats/min at peak (p< 0.0001) with a concomitant change in systolic blood pressure (143 ± 35 vs. 167 ± 38 mmHg; p = 0.001) but no change in diastolic blood pressure (74 ± 19 vs. 75 ± 18 mmHg; p = NS). Target heart rate was achieved in 20 of 47 (43%) patients with accelerated dobutamine alone and in 34 of 47 (72%) with the addition of atropine. An average of 11.6 ± 3.7 min was required to obtain target heart rate. Subjective sensations from the dobutamine occurred in 49% of patients (palpitations 21%, nausea 6%, chest pain 6%, headache 6%, dizziness 13%), mild arrhythmia in 48% of patients (ventricular premature beats 38%, supraventricular tachycardia 10%), and one patient had nonsustained ventricular tachycardia.
Conclusion: A single, high‐dose (40 mcg/kg/min) dobutamine‐atropine protocol provides an efficient means of performing dobutamine stress echocardiography with a similar symptom profile as conventional dobutamine infusion protocols in patients with a high pretest probability of CAD. Randomized, controlled studies will be necessary to assess the sensitivity and specificity of this accelerated dobutamine echo protocol.
Keywords: pharmacologic stress testing, atherosclerosis, echocardiography, dobutamine, stress echocardiography
Full Text
The Full Text of this article is available as a PDF (433.8 KB).
References
- 1. Poldermans D., Fioretti PM, Boersma E., Forster T., Urk HV, Cornei JH, Arnese M., Roelandt JRTC, Safety of dobutamine‐atropine stress echocardiography in patients with suspected or proven coronary artery disease. Am J Cardiol 1994; 73: 456–459 [DOI] [PubMed] [Google Scholar]
- 2. Arky R., Physicians' Desk Reference, p. 1451 New Jersey: Medical Economics Company, 1998. [Google Scholar]
- 3. Secknus MA, Marwick T., Evolution of dobutamine echocardiography protocols and indications: Safety and side effects in 3,011 studies over 5 years. J Am Coll Cardiol 1997: 29; 1234–1240 [DOI] [PubMed] [Google Scholar]
- 4. Pellikka PA, Roger VL, McCully RB, Mahoney DW, Bailley KR, Seward JB, Tajik AJ, Normal stroke volume and cardiac output response during dobutamine stress echocardiography in subjects without left ventricular wall motion abnormalities. Am J Cardiol 1995: 76 (12): 881–886 [DOI] [PubMed] [Google Scholar]
- 5. McNeill AJ, Fioretti PM, El‐Daid EM, Salustri A., Forster T., Roelandt JRTC, Enhanced sensitivity for detection of coronary artery disease by addition of atropine to dobutamine stress echocardiography. Am J Cardiol 1992; 70: 41–46 [DOI] [PubMed] [Google Scholar]
- 6. Ling LH, Pellikka PA, Mahoney DW, McCully BR, Roger VL, Seward JB, Atropine augmentation in dobutamine stress echocardiography: Role and incremental value in a clinical practice setting. J Am Coll Cardiol 1996; 28: 551–557 [DOI] [PubMed] [Google Scholar]
- 7. Weissman NJ, Nidorf SM, Guerrero L., Weyman AE, Picard MH, Optimal stage duration in dobutamine stress echocardiography. J Am Coll Cardiol 1995; 25: 605–609 [DOI] [PubMed] [Google Scholar]
- 8. Weissman NJ, Rose GA, Foster GP, Picard MH, Effect of prolonging peak dobutamine dose during stress echocardiography. J Am Coll Cardiol 1997; 29: 526–530 [DOI] [PubMed] [Google Scholar]
- 9. Smart SC, Sawada S., Ryan T., Segar D., Atherton L., Berkovitz K., Bourdillon PDV, Feigenbaum H., Low‐dose dobutamine echocardiography detects reversible dysfunction after thrombolytic therapy of acute myocardial infarction. Circulation 1993; 88: 405–415 [DOI] [PubMed] [Google Scholar]
- 10. Sedlis ST, Lorin J., Matalon A., Chandrasekaran S., Gold J., Santini C., Negron M., Kumar K., Steinberg EH, Dobutamine stress testing in the cardiac catheterization laboratory. Am J Cardiol 1996; 78: 340–343 [DOI] [PubMed] [Google Scholar]
- 11. Mertes H., Sawada SG, Ryan T., Segar DS, Kovacs R., Roltz J., Feigenbaum H., Symptoms, adverse effects, and complications associated with dobutamine stress echocardiography. Circulation 1993; 88: 15–19 [DOI] [PubMed] [Google Scholar]